RPRD1B在人卵巢癌细胞系中高表达并促进肿瘤细胞增殖

doi:10.16352/j.issn.1001-6325.2025.08.1066

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (8): 1066-1072.doi: 10.16352/j.issn.1001-6325.2025.08.1066

RPRD1B在人卵巢癌细胞系中高表达并促进肿瘤细胞增殖

田野^1,2, 何权^1,2, 王小娟^3*

1.清华大学北京清华长庚医院清华大学临床医学院,北京 102218;
2.清华大学器官移植与仿生医学研究院,北京 102218;
3.清华大学北京清华长庚医院清华大学临床医学院肝胆胰中心,北京 102218

收稿日期:2025-04-23 修回日期:2025-06-10 出版日期:2025-08-05 发布日期:2025-07-11
通讯作者: ^*wxj0250@163.com

RPRD1B is highly expressed in human ovarian cancer cell lines and promotes tumor cell proliferation

TIAN Ye^1,2, HE Quan^1,2, WANG Xiaojuan^3*

1. Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218;
2. Institute for Organ Transplant and Bionic Medicine, Tsinghua University, Beijing 102218;
3. Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China

Received:2025-04-23 Revised:2025-06-10 Online:2025-08-05 Published:2025-07-11
Contact: ^*wxj0250@163.com

摘要/Abstract

摘要： 目的探究核前体mRNA结构域调控蛋白1B(RPRD1B)在人卵巢癌中的作用。方法利用RT-qPCR和Western blot实验检测卵巢癌中RPRD1B的表达水平。基于CRISPR/Cas9及慢病毒系统构建RPRD1B敲除和过表达细胞系A2780和SKOV3,利用划痕、Transwell实验以及小鼠皮下成瘤模型验证其在卵巢癌中的功能。结果 RPRD1B在卵巢癌中高表达(P＜0.001)。敲除RPRD1B抑制卵巢癌细胞集落形成和增殖能力(P＜0.001),以及细胞迁移(P＜0.05)和侵袭能力(P＜0.001)。同时,敲除RPRD1B抑制SKOV3卵巢癌细胞在小鼠体内成瘤能力(P＜0.001)。结论 RPRD1B在多个人卵巢癌细胞系中高表达,并促进小鼠皮下肿瘤生长。

关键词: 核前体mRNA结构域调控蛋白1B(RPRD1B), 卵巢癌, 增殖

Abstract: Objective To explore the role of regulation of nuclear pre-mRNA-domain-containing 1B(RPRD1B)in human ovarian cancer. Methods The expression level of RPRD1B in ovarian cancer was detected by RT-qPCR and Western blot experiments. Based on the CRISPR/Cas9 system and lentiviral system, the A2780 and SKOV3 cell lines with RPRD1B gene knockout and over-expression were respectively constructed, and their functions in ovarian cancer were verified by wound-healing assay, Transwell assay and mouse subcutaneous tumor formation model. Results RPRD1B was highly expressed in ovarian cancer cell lines (P＜0.001). Knockout of RPRD1B inhibited the colony formation and proliferation ability of ovarian cancer cells (P＜0.001), as well as the cell migration (P＜0.05) and invasion ability (P＜0.001). Meanwhile, knockout of RPRD1B inhibited the tumorigenesis ability of SKOV3 ovarian cancer cell lines in vivo (P＜0.001). Conclusions RPRD1B is highly expressed in human ovarian cancer cell lines and promotes the growth of subcutaneous tumors in mice.

Key words: regulation of nuclear pre-mRNA-domain-containing 1B (RPRD1B), ovarian cancer, proliferation

中图分类号:

田野, 何权, 王小娟. RPRD1B在人卵巢癌细胞系中高表达并促进肿瘤细胞增殖[J]. 基础医学与临床, 2025, 45(8): 1066-1072.

TIAN Ye, HE Quan, WANG Xiaojuan. RPRD1B is highly expressed in human ovarian cancer cell lines and promotes tumor cell proliferation[J]. Basic & Clinical Medicine, 2025, 45(8): 1066-1072.

参考文献 14

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Cancer J Clin, 2021, 71, 209-249.
[2]	Jayson GC, Kohn EC, Kitchener, et al. Ovarian cancer[J]. Lancet, 2014, 384, 1376-1388.
[3]	Hinchcliff E, Westin SN, Herzog TJ. State of the science: contemporary front-line treatment of advanced ovarian cancer[J]. Gynecol Oncol, 2022, 166, 18-24.
[4]	Bartoletti M, Musacchio L, Giannone G, et al. Emerging molecular alterations leading to histology-specifictargeted therapies in ovarian cancer beyond PARP inhibitors[J]. Cancer Treat Rev, 2021, 101:102298. doi: 10.1016/j.ctrv.2021.102298.
[5]	Gogineni V, Morand S, Staats H, et al. Current ovarian cancer maintenance strategies and promising new developments[J]. Cancer, 2021, 12:38-53.
[6]	González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2019, 381:2391-2402.
[7]	Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer[J]. N Engl J Med, 2019, 381:2416-2428.
[8]	Li M, Ma D, Chang Z. Current understanding of CREPT and p15RS, carboxy-terminal domain (CTD)-interacting proteins, in human cancers[J]. Oncogene, 2021, 40:705-716.
[9]	Li W, Zheng G, Xia J, et al. Cell cycle related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in nonsmall-cell lung cancer[J]. Cancer Sci, 2018, 109:1012-1023.
[10]	Jiang J, Yang X, He X, et al. MicroRNA449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/beta-catenin signaling[J]. Chem Biol Interact, 2019, 302:74-82
[11]	Sun M, Si G, Sun HS, et al. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway[J]. Biochem Biophys Res Commun, 2018, 496:1183-1190.
[12]	Lu D, Wu Y, Wang Y, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes[J]. Cancer Cell, 2012, 21: 92-104.
[13]	Zhai W, Ye X, Wang Y, et al. CREPT/RPRD1B promotes tumorigenesis through STAT3-driven gene transcription in a p300-dependent manner[J]. Br J Cancer, 2021, 124: 1437-1448.
[14]	Manfioletti G, Fedele M. Epithelial-mesenchymal transition (EMT)[J]. Int J Mol Sci, 2023, 24:11386. doi: 10.3390/ijms241411386.

[1]	程志坚, 王国毓, 贺西京, 翟静静, 王涛宁. 小鼠骨髓来源巨噬细胞原代培养中NG2表达及生物活性[J]. 基础医学与临床, 2026, 46(1): 1-4.
[2]	韦新闻, 温小军, 樊钊强, 劳锡峰, 张鲁青, 钟鸣. CircAPLP2通过调节miR-455-3p/STMN1轴抑制人结直肠癌细胞系增殖、迁移和侵袭[J]. 基础医学与临床, 2025, 45(9): 1208-1214.
[3]	安信, 贾麟, 马吾苏木·马木特, 黄志鹏, 卡哈尔曼·斯拉木, 热夏提·热合曼, 海日拉·吾拉木, 库尔班江·阿布力克木, 加素尔·巴吐尔. ANGPT1影响小鼠前列腺癌细胞系RM-1增殖、侵袭及血管生成[J]. 基础医学与临床, 2025, 45(9): 1165-1172.
[4]	邹庆波, 张国臣, 潘长景. 绞股蓝皂苷抑制人前列腺癌细胞系PC-3增殖、迁移和侵袭[J]. 基础医学与临床, 2025, 45(8): 1059-1065.
[5]	赵翠娟, 敖民, 武文博, 李妍华. 高脂饮食加重小鼠肠易激综合征肠屏障损伤[J]. 基础医学与临床, 2025, 45(8): 1022-1027.
[6]	殷利军, 卜阳, 昂格勒玛, 宋琳琳. LncRNA HIF1A-AS1通过干预HIF1A促进胃癌细胞系增殖[J]. 基础医学与临床, 2025, 45(5): 627-636.
[7]	魏建新, 房彦乐, 鲁雨博, 高宇光, 郎兴, 李静涛, 马新生. 青蒿琥酯抑制肾母细胞瘤细胞系SK-NEP-1增殖和促进凋亡与自噬[J]. 基础医学与临床, 2025, 45(4): 493-498.
[8]	周晶, 屈苗. 上调miR-152抑制ox-LDL诱导的人血管平滑肌细胞增殖和迁移[J]. 基础医学与临床, 2025, 45(4): 486-492.
[9]	张瑶, 张璇, 贾安娜, 战世佳, 郭金鑫, 常艳, 郭永丽. 嗅素结构域家族蛋白3促进MYCN扩增型神经母细胞瘤细胞系体外增殖[J]. 基础医学与临床, 2025, 45(2): 168-175.
[10]	李文辉, 任红岗, 郭剑, 宋洋, 冯富强. miR-141-3p下调溶血磷脂酸受体3抑制脑胶质瘤细胞增殖、迁移和上皮-间质转化[J]. 基础医学与临床, 2025, 45(12): 1580-1587.
[11]	韩伟, 潘伟, 张曼, 高翔宇, 康心凯, 朱志博, 刘瑞廷. 滨蒿内酯抑制结肠癌细胞系HCT116的增殖和侵袭[J]. 基础医学与临床, 2025, 45(11): 1429-1437.
[12]	杜红蕾, 张锋, 郭海彦, 徐宁, 吴震. 大车前苷抑制人胃癌细胞系BGC823增殖和侵袭[J]. 基础医学与临床, 2025, 45(10): 1333-1340.
[13]	申红梅, 于燕, 冯绪强, 王克强. 松萝酸抑制人卵巢癌细胞系增殖[J]. 基础医学与临床, 2025, 45(1): 31-37.
[14]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[15]	姚安军, 陈凌子, 金惠仙. 二十二碳六烯酸抑制人结肠癌细胞系HT-29增殖[J]. 基础医学与临床, 2024, 44(8): 1107-1112.

RPRD1B在人卵巢癌细胞系中高表达并促进肿瘤细胞增殖

RPRD1B is highly expressed in human ovarian cancer cell lines and promotes tumor cell proliferation

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 14

相关文章 15

编辑推荐

Metrics

本文评价